DANVERS, Mass.--(BUSINESS WIRE)--The United States Food and Drug Administration (FDA) has granted breakthrough device designation to Abiomed’s (NASDAQ: ABMD) Impella ECP expandable percutaneous heart ...
Longer times from symptom onset to randomization equaled a smaller—or perhaps no—advantage for Impella vs standard care.
Abiomed (NASDAQ: ABMD) announces the results of PROTECT III, the ongoing, prospective, single-arm FDA post-approval study for the PMA approval of Impella 2.5 and Impella CP in high-risk PCI. PROTECT ...
A new life-saving technology was used during a heartfelt reunion thanks to the world’s smallest heart pump, Impella, giving patients a second chance at life ...
DANVERS, Mass. – October 28, 2024 – Results were presented at Transcatheter Cardiovascular Therapeutics (TCT) 2024 conference from the first completed pivotal trial on patients supported with Impella ...
Abiomed, also now known as Johnson & Johnson MedTech, issued a recall for its Impella RP with SmartAssist and Impella RP Flex with SmartAssist heart pumps due to safety concerns. The recall involves ...
The US Food and Drug Administration (FDA)-approved labeling for the Impella 5.0 and Impella LD heart pumps (Abiomed) has been expanded to allow for longer support time in critically ill patients, the ...
Abiomed, part of Johnson & Johnson MedTech, recently presented positive results from the first completed pivotal trial on Impella ECP, a novel transvalvular axial flow pump with compressible pump ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results